255 related articles for article (PubMed ID: 17367910)
1. IL-28 and IL-29: newcomers to the interferon family.
Uzé G; Monneron D
Biochimie; 2007; 89(6-7):729-34. PubMed ID: 17367910
[TBL] [Abstract][Full Text] [Related]
2. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling.
Dumoutier L; Tounsi A; Michiels T; Sommereyns C; Kotenko SV; Renauld JC
J Biol Chem; 2004 Jul; 279(31):32269-74. PubMed ID: 15166220
[TBL] [Abstract][Full Text] [Related]
3. Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control.
Andreakos E; Zanoni I; Galani IE
Curr Opin Immunol; 2019 Feb; 56():67-75. PubMed ID: 30399529
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of interleukins-28 and -29: comparison with type I interferons.
Meager A; Visvalingam K; Dilger P; Bryan D; Wadhwa M
Cytokine; 2005 Jul; 31(2):109-18. PubMed ID: 15899585
[TBL] [Abstract][Full Text] [Related]
5. Antiviral effect of interferon lambda against West Nile virus.
Ma D; Jiang D; Qing M; Weidner JM; Qu X; Guo H; Chang J; Gu B; Shi PY; Block TM; Guo JT
Antiviral Res; 2009 Jul; 83(1):53-60. PubMed ID: 19501257
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 27, like interferons, activates JAK-STAT signaling and promotes pro-inflammatory and antiviral states that interfere with dengue and chikungunya viruses replication in human macrophages.
Valdés-López JF; Hernández-Sarmiento LJ; Tamayo-Molina YS; Velilla-Hernández PA; Rodenhuis-Zybert IA; Urcuqui-Inchima S
Front Immunol; 2024; 15():1385473. PubMed ID: 38720890
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Type III Interferon (IFN) Genes
Peterson ST; Kennedy EA; Brigleb PH; Taylor GM; Urbanek K; Bricker TL; Lee S; Shin H; Dermody TS; Boon ACM; Baldridge MT
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462571
[TBL] [Abstract][Full Text] [Related]
8. De novo developed protein binders mimicking Interferon lambda signaling.
Kolářová L; Zahradník J; Huličiak M; Mikulecký P; Peleg Y; Shemesh M; Schreiber G; Schneider B
FEBS J; 2022 May; 289(9):2672-2684. PubMed ID: 34826176
[TBL] [Abstract][Full Text] [Related]
9. [Action of type III IFNs and their roles in immune responses].
Domagalski K; Tretyn A; Pawłowska M; Szczepanek J; Halota W
Postepy Hig Med Dosw (Online); 2010 Oct; 64():522-33. PubMed ID: 21109705
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
11. Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance.
Pervolaraki K; Rastgou Talemi S; Albrecht D; Bormann F; Bamford C; Mendoza JL; Garcia KC; McLauchlan J; Höfer T; Stanifer ML; Boulant S
PLoS Pathog; 2018 Nov; 14(11):e1007420. PubMed ID: 30485383
[TBL] [Abstract][Full Text] [Related]
12. Interferon: cellular executioner or white knight?
Maher SG; Romero-Weaver AL; Scarzello AJ; Gamero AM
Curr Med Chem; 2007; 14(12):1279-89. PubMed ID: 17504213
[TBL] [Abstract][Full Text] [Related]
13. Interferon-lambda: a new addition to an old family.
Donnelly RP; Kotenko SV
J Interferon Cytokine Res; 2010 Aug; 30(8):555-64. PubMed ID: 20712453
[TBL] [Abstract][Full Text] [Related]
14. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
Liu B; Chen S; Guan Y; Chen L
PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
[TBL] [Abstract][Full Text] [Related]
15. Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-λ.
Jacobs S; Wavreil F; Schepens B; Gad HH; Hartmann R; Rocha-Pereira J; Neyts J; Saelens X; Michiels T
J Interferon Cytokine Res; 2018 Nov; 38(11):469-479. PubMed ID: 30335553
[TBL] [Abstract][Full Text] [Related]
16. Interferons lambda, new cytokines with antiviral activity.
Lopušná K; Režuchová I; Betáková T; Skovranová L; Tomašková J; Lukáčiková L; Kabát P
Acta Virol; 2013; 57(2):171-9. PubMed ID: 23600875
[TBL] [Abstract][Full Text] [Related]
17. Novel type III interferons produce anti-tumor effects through multiple functions.
Li Q; Kawamura K; Tada Y; Shimada H; Hiroshima K; Tagawa M
Front Biosci (Landmark Ed); 2013 Jun; 18(3):909-18. PubMed ID: 23747856
[TBL] [Abstract][Full Text] [Related]
18. Basal interferon signaling and therapeutic use of interferons in controlling rotavirus infection in human intestinal cells and organoids.
Hakim MS; Chen S; Ding S; Yin Y; Ikram A; Ma XX; Wang W; Peppelenbosch MP; Pan Q
Sci Rep; 2018 May; 8(1):8341. PubMed ID: 29844362
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
[TBL] [Abstract][Full Text] [Related]
20. Type III interferon is a critical regulator of innate antifungal immunity.
Espinosa V; Dutta O; McElrath C; Du P; Chang YJ; Cicciarelli B; Pitler A; Whitehead I; Obar JJ; Durbin JE; Kotenko SV; Rivera A
Sci Immunol; 2017 Oct; 2(16):. PubMed ID: 28986419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
